LncRNA TAT-AS1 promotes the progression of breast cancer through the hsa-miR-3187-5p/RUNX1 axis and its clinical value

Breast cancer (BC) poses a serious threat to women’s health, and its diagnosis and treatment remain extremely challenging in clinical practice. This study aims to clarify the mechanism by which lncRNA TAT-AS1 affects BC and evaluate its clinical value. LncRNA TAT-AS1, miR-3187-5p, and RUNX1 mRNA levels were determined using RT-qPCR. Cell proliferation, apoptosis, migration, and invasion of cells were determined using CCK-8, flow cytometry, and Transwell assay. The targeted relationships between genes were verified through dual luciferase reporter assays, RNA pull-down assays, and RIP assays. In BC patients, lncRNA TAT-AS1 and RUNX1 were upregulated in plasma, while miR-3187-5p was downregulated. miR-3187-5p was a downstream target of lncRNA TAT-AS1 and has a targeted binding relationship with RUNX1. Through the miR-3187-5p/RUNX1 axis, lncRNA TAT-AS1 promoted BC cell proliferation, apoptosis, migration, and invasion. The lncRNA TAT-AS1 may have the ability to distinguish BC, and the discovery of the lncRNA TAT-AS1/miR-3187-5p/RUNX1 regulatory axis provides a new strategy for targeted therapy.